US stocks fell on Friday to close the week as a negative mix of news related to traders worried about tariffs and inflation.
Friday’s losses left a major average in negative territory the week. The 30-stock Dow Jones Industrial Arage abandoned 0.5%, the S&P 500 soaked 0.2%, and the high-tech NASDAQ composite fell by 0.5%.
Source: Investing.com
The next week is expected to be another eventful as investors measure the outlook for the economy, inflation and interest rates.
On the economic calendar, the US Consumer Price Inflation Report on Wednesday in January is the most important thing, and can cause even more confusion if it is higher than expected. CPI data is accompanied by the release of the latest figures on producer prices. This will help you fill out photos of inflation paintings, similar to the January retail sales report.
Meanwhile, if Chairman Jerome Powell gives a six-monthly monetary policy testimony before the House Financial Services Committee on Tuesday and Wednesday, the Federal Reserve fee views could be revealed.
Source: Investing.com
Traders are now hoping that the US Central Bank will cut interest rates only once this year, and have retreated from previous bets on two interest rate cuts since June, according to the Investing.com Fed Monitor Tool.
Elsewhere, busy revenue seasons include Cisco Systems (NASDAQ: CSCO), Shopify (NYSE: SHOP), COINBASE (NASDAQ: COIN), ROBINHOOD (NASDAQ: HOOD), Applovin (NASDAQ: APP), Reddit (Nyse) Continued with a report from. rddt), Palo Alto Networks (NASDAQ: PANW), McDonald’s (NYSE: MCD), Coca-Cola (NYSE: KO), Modanya (NASDAQ: mRNA), CVS Health (NYSE: CVS), Airbnb (NASDAQ: ABNB), and Do Ordash (Nasdaq: Dash).
Regardless of which direction the market is heading, below highlights stocks that are likely to be in demand and other stocks where new shortcomings can be seen. However, my time frame is just Monday, February 10th – last week, Friday, February 14th.
Robinhood, a fee-free trading app popular with retail investors, is set to report a fourth-quarter revenue update after 4:05pm ET on Wednesday, Expectations are high.
Market participants predict a substantial swing in food stock after a drop in printing, according to the options market, allowing for 12.4% implicit movement in either direction. Indications of increased confidence, the company has recently received three upward profit forecast revisions, with zero downward revisions.
Source: InvestingPro
Analysts forecast earnings per share (EPS) to be $0.52, representing a staggering increase from earnings of $0.03 in the same period last year. Revenues are expected to nearly double year-on-year as Robinhood continues to expand its user base and leverage new momentum in crypto and stock trading.
The company has established itself as a leader in the retail investment field, benefiting from growing interest in stocks and crypto trading. Robinhood’s improved operational efficiency and cost-cutting measures also increase profitability.
Additionally, retail brokerages have moved to diversifying revenue streams, particularly through growing options trading and subscription-based products.
Source: Investing.com
Robinhood shares are in tears and have hit a series of record highs in recent sessions. Hood closed at $55.86 on Friday, earning the company a $49.4 billion valuation. So far in 2025, stock prices have risen 50%, with optimism being built around its ability to profit from a revived wave of retail trading.
Additionally, Robinhood shows impressive financial health, boasting an Investing Pro Health score of 3.2 out of 5.0 (“Great”).
Meanwhile, Modanya is facing significant headwinds heading towards her fourth quarter revenue report, scheduled to be released later this week. The results show that the expected travel is up and down by around 11% ahead of the bell, which will take place at 6:35am ET on Friday.
Once luxury vaccine makers struggle with lower demand for COVID-19 shots, and analysts hope they are concerned about revenue growth, lower production costs and lack of diversification . In the three months leading up to revenue updates, analysts reduced EPS estimates 12 times compared to zero upward revisions.
Source: InvestingPro
Moderna is planning to record a loss of $2.70 per share. This is a sharp reversal from the $0.55 profit recorded a year ago. Revenue is expected to plummet nearly 70% from the previous year to $951.1 million.
Biotechnology companies now face revenue growth challenges with limited short-term catalysts to offset the decline in demand as vaccine sales continue to decline.
Moderna’s non-covid pipeline offers little short-term relief. Its experimental influenza and RSV vaccines are lagging behind established players and are overly dependent on a downsizing market.
Source: Investing.com
mRNA strains ended Friday’s session at $32.60. It wasn’t too far from the last 52 weeks’ low of $31.94. This was the weakest level since April 2020. At its current valuation, Moderna’s market capitalization is $12.5 billion. Stocks trading below the main moving average have fallen 21.6% to start the new year.
Additionally, Moderna holds a below average InvestingPro Financial Health score of 2.1 out of 5.0, reflecting concerns about declining revenue performance and slowing growth outlook.
Whether you’re a beginner investor or a veteran trader, leverage InvestingPro Unlock the world of investment opportunities while minimizing risk in a challenging market background.
•Propicks AI: A proven track record for AI-selected stock recipient.
•Investment Professional Value: Immediately check if the stock is low or excessive.
• Advanced Stock Screener: Search for the best inventory based on hundreds of selected filters and criteria.
•Top ideas: See what billionaires investors such as Warren Buffett, Michael Barry and George Soros are buying.
Disclosure: At the time of writing, the Nasdaq 100 is long via the S&P 500, SPDR®S&P 500 ETF (SPY), and Investco QQQ Trust ETF (QQQ). It is also long on the Invesco Top QQQ ETF (QBIG), Invesco S&P 500 Equivalent Weight ETF (RSP), and Vaneck Vectors Semiconductor ETF (SMH).
I regularly rebalance my individual stock and ETF portfolio based on a continuous risk assessment of both the macroeconomic environment and the corporate finances.
The views discussed in this article are the only opinions of the authors and should not be taken as investment advice.
Follow Jesse Cohen on X/Twitter @jessecoheninv More stock market analysis and insights.
